In this section
@article{Popescu:2020:10.1002/hbm.25133,
author = {Popescu, SG and Whittington, A and Gunn, RN and Matthews, PM and Glocker, B and Sharp, DJ and Cole, JH},
doi = {10.1002/hbm.25133},
journal = {Human Brain Mapping},
pages = {4406--4418},
title = {Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease},
url = {http://dx.doi.org/10.1002/hbm.25133},
volume = {41},
year = {2020}
}
TY - JOUR
AB - Multiple biomarkers can capture different facets of Alzheimer's disease. However, statistical models of biomarkers to predict outcomes in Alzheimer's rarely model nonlinear interactions between these measures. Here, we used Gaussian Processes to address this, modelling nonlinear interactions to predict progression from mild cognitive impairment (MCI) to Alzheimer's over 3 years, using Alzheimer's Disease Neuroimaging Initiative (ADNI) data. Measures included: demographics, APOE4 genotype, CSF (amyloidβ42, total tau, phosphorylated tau), [18F]florbetapir, hippocampal volume and brainage. We examined: (a) the independent value of each biomarker; and (b) whether modelling nonlinear interactions between biomarkers improved predictions. Each measured added complementary information when predicting conversion to Alzheimer's. A linear model classifying stable from progressive MCI explained over half the variance (R2 = 0.51, p < .001); the strongest independently contributing biomarker was hippocampal volume (R2 = 0.13). When comparing sensitivity of different models to progressive MCI (independent biomarker models, additive models, nonlinear interaction models), we observed a significant improvement (p < .001) for various twoway interaction models. The best performing model included an interaction between amyloidβPET and Ptau, while accounting for hippocampal volume (sensitivity = 0.77, AUC = 0.826). Closely related biomarkers contributed uniquely to predict conversion to Alzheimer's. Nonlinear biomarker interactions were also implicated, and results showed that although for some patients adding additional biomarkers may add little value (i.e., when hippocampal volume is high), for others (i.e., with low hippocampal volume) further invasive and expensive examination may be warranted. Our framework enables visualisation of these interactions, in individual patient biomarker ‘space', providing information for per
AU - Popescu,SG
AU - Whittington,A
AU - Gunn,RN
AU - Matthews,PM
AU - Glocker,B
AU - Sharp,DJ
AU - Cole,JH
DO - 10.1002/hbm.25133
EP - 4418
PY - 2020///
SN - 1065-9471
SP - 4406
TI - Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease
T2 - Human Brain Mapping
UR - http://dx.doi.org/10.1002/hbm.25133
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000546429000001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://onlinelibrary.wiley.com/doi/10.1002/hbm.25133
UR - http://hdl.handle.net/10044/1/83558
VL - 41
ER -
Established in 2017 by its principal funder the Medical Research Council, in partnership with Alzheimer's Society and Alzheimer’s Research UK, The UK Dementia Research Institute (UK DRI) is the UK’s leading biomedical research institute dedicated to neurodegenerative diseases.
